JP2021524247A5 - - Google Patents

Info

Publication number
JP2021524247A5
JP2021524247A5 JP2020565264A JP2020565264A JP2021524247A5 JP 2021524247 A5 JP2021524247 A5 JP 2021524247A5 JP 2020565264 A JP2020565264 A JP 2020565264A JP 2020565264 A JP2020565264 A JP 2020565264A JP 2021524247 A5 JP2021524247 A5 JP 2021524247A5
Authority
JP
Japan
Prior art keywords
sequence
antigen
nucleic acid
vector
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2020565264A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021524247A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/033828 external-priority patent/WO2019226939A1/en
Publication of JP2021524247A publication Critical patent/JP2021524247A/ja
Publication of JP2021524247A5 publication Critical patent/JP2021524247A5/ja
Withdrawn legal-status Critical Current

Links

JP2020565264A 2018-05-23 2019-05-23 免疫チェックポイント阻害剤の共発現ベクター Withdrawn JP2021524247A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862675624P 2018-05-23 2018-05-23
US62/675,624 2018-05-23
PCT/US2019/033828 WO2019226939A1 (en) 2018-05-23 2019-05-23 Immune checkpoint inhibitor co-expression vectors

Publications (2)

Publication Number Publication Date
JP2021524247A JP2021524247A (ja) 2021-09-13
JP2021524247A5 true JP2021524247A5 (cg-RX-API-DMAC7.html) 2022-05-27

Family

ID=68617211

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020565264A Withdrawn JP2021524247A (ja) 2018-05-23 2019-05-23 免疫チェックポイント阻害剤の共発現ベクター

Country Status (9)

Country Link
US (2) US20210213122A1 (cg-RX-API-DMAC7.html)
EP (1) EP3796930A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021524247A (cg-RX-API-DMAC7.html)
KR (1) KR20210013589A (cg-RX-API-DMAC7.html)
CN (1) CN112351793A (cg-RX-API-DMAC7.html)
AU (1) AU2019275070A1 (cg-RX-API-DMAC7.html)
CA (1) CA3099642A1 (cg-RX-API-DMAC7.html)
TW (1) TW202000906A (cg-RX-API-DMAC7.html)
WO (1) WO2019226939A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105190656B (zh) 2013-01-17 2018-01-16 佩索纳里斯公司 用于遗传分析的方法和系统
US10125399B2 (en) 2014-10-30 2018-11-13 Personalis, Inc. Methods for using mosaicism in nucleic acids sampled distal to their origin
US11299783B2 (en) 2016-05-27 2022-04-12 Personalis, Inc. Methods and systems for genetic analysis
KR102945203B1 (ko) 2017-05-08 2026-03-31 시애틀 프로젝트 코포레이션 알파바이러스 신생항원 벡터
CN112739375B (zh) * 2018-08-17 2025-10-28 磨石生物公司 靶向共同抗原的抗原结合蛋白
KR20210090650A (ko) * 2018-11-07 2021-07-20 그릿스톤 바이오, 인코포레이티드 알파바이러스 신생항원 벡터 및 인터페론 억제제
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
SG11202113187WA (en) 2019-05-30 2021-12-30 Gritstone Bio Inc Modified adenoviruses
JP7470787B2 (ja) 2019-11-05 2024-04-18 パーソナリス,インコーポレイティド 単一試料からの腫瘍純度の推定
EP4061405A1 (en) 2019-11-18 2022-09-28 Janssen Biotech, Inc. Vaccines based on mutant calr and jak2 and their uses
EP4168569A4 (en) * 2020-06-18 2024-08-07 Personalis, Inc. Machine-learning techniques for predicting surface-presenting peptides
EP4175664A2 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2022009049A1 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
IL300026A (en) 2020-08-06 2023-03-01 Gritstone Bio Inc Multiepitope vaccine cassettes
WO2022082030A2 (en) 2020-10-15 2022-04-21 Gritstone Bio, Inc. Antigen-binding proteins and related methods of use
WO2022155503A1 (en) 2021-01-14 2022-07-21 Gritstone Bio, Inc. Multi-specific antibodies and methods of use
WO2022229966A1 (en) 2021-04-29 2022-11-03 Yeda Research And Development Co. Ltd. T cell receptors directed against ras-derived recurrent neoantigens and methods of identifying same
JP2024533123A (ja) * 2021-09-02 2024-09-12 エリクサージェン セラピューティクス,インコーポレイティド がんのための温度制御可能なrna免疫療法
WO2023059654A1 (en) 2021-10-05 2023-04-13 Personalis, Inc. Customized assays for personalized cancer monitoring
WO2026006629A1 (en) 2024-06-27 2026-01-02 Personalis, Inc. System and method for management of compressed sequencing files

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0803573A1 (en) * 1996-04-25 1997-10-29 Gesellschaft für Biotechnologische Forschung mbH (GBF) Polycistronic expression construct with cytokines for multivalent vaccines
WO2002061113A2 (en) * 2001-02-01 2002-08-08 The Johns Hopkins University Nucleic acid derived vaccine that encodes an antigen linked to a polypeptide that promotes antigen presentation
AU2002327338A1 (en) * 2001-07-25 2003-02-17 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
EP1571909A4 (en) * 2002-10-03 2009-11-11 Idm Pharma Inc OPTIMIZED MULTIPOPOP CONSTRUCTS AND USES THEREOF
US9402888B2 (en) * 2013-03-14 2016-08-02 The Wistar Institute Of Anatomy And Biology Methods and compositions for treating cancer
JP7060324B2 (ja) * 2013-12-20 2022-04-26 ザ・ブロード・インスティテュート・インコーポレイテッド ネオ抗原ワクチンによる併用療法
KR20190062617A (ko) * 2014-09-03 2019-06-05 버베리안 노딕 에이/에스 면역 반응을 증대시키기 위한 방법 및 조성물
CN108601820A (zh) * 2015-10-12 2018-09-28 南托米克斯有限责任公司 用于病毒癌症新表位的组合物和方法
WO2017151940A2 (en) * 2016-03-03 2017-09-08 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
WO2017152042A2 (en) * 2016-03-04 2017-09-08 New York University Virus vectors expressing multiple epitopes of tumor associated antigens for inducing antitumor immunity
WO2017192924A1 (en) * 2016-05-04 2017-11-09 Fred Hutchinson Cancer Research Center Cell-based neoantigen vaccines and uses thereof
RU2019119272A (ru) * 2016-11-23 2020-12-24 Гритстоун Онколоджи, Инк. Вирусная доставка неоантигенов
WO2018161092A1 (en) * 2017-03-03 2018-09-07 New York University Induction and enhancement of antitumor immunity involving virus vectors expressing multiple epitopes of tumor associated antigens and immune checkpoint inhibitors or proteins

Similar Documents

Publication Publication Date Title
JP2022534282A5 (cg-RX-API-DMAC7.html)
JP2021525076A5 (cg-RX-API-DMAC7.html)
RU2019119272A (ru) Вирусная доставка неоантигенов
JP2022512912A5 (cg-RX-API-DMAC7.html)
JP2023526495A5 (cg-RX-API-DMAC7.html)
Kastelein et al. Lysis gene expression of RNA phage MS2 depends on a frameshift during translation of the overlapping coat protein gene
JP2023541108A5 (cg-RX-API-DMAC7.html)
JP2023521662A5 (cg-RX-API-DMAC7.html)
JP2021501572A5 (cg-RX-API-DMAC7.html)
CN111328420B (zh) 用于预防和治疗微卫星不稳定(msi)癌症的基于共有肿瘤新抗原的通用疫苗
JP2021524247A (ja) 免疫チェックポイント阻害剤の共発現ベクター
JP2022539417A5 (cg-RX-API-DMAC7.html)
JP2023523414A5 (cg-RX-API-DMAC7.html)
CN118414426A (zh) 产生环状rna的单罐法
JP2023523413A5 (cg-RX-API-DMAC7.html)
JPS61143327A (ja) 多効果免疫性蛋白質
JP5148116B2 (ja) 癌胎児性抗原融合タンパク質及びその使用
CN115942942A (zh) 感染性疾病抗原和疫苗
JP2004501646A5 (cg-RX-API-DMAC7.html)
US11976274B2 (en) Methods and compositions for identifying neoantigens for use in treating and preventing cancer
RU2019112725A (ru) Композиции и способы для повышения стабильности трансгенов в поксвирусах
JP2005509420A5 (cg-RX-API-DMAC7.html)
JP2025513022A5 (cg-RX-API-DMAC7.html)
CN117587070B (zh) 一种经遗传修饰的非人哺乳动物的制备方法及应用
JP2024503108A5 (cg-RX-API-DMAC7.html)